Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Immunotherapy has emerged in recent years and has revolutionized the treatment of cancer. Immune checkpoint inhibitors, including anti-cytotoxic T lymphocyte antigen-4 (CTLA-4), anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) agents, are the first of this new generation of treatments. Anti-PD-1/PD-L1 agents targe...
Alternative Titles
Full title
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2259305168
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2259305168
Other Identifiers
ISSN
0114-5916
E-ISSN
1179-1942
DOI
10.1007/s40264-018-0774-8
